5alpha-reductase inhibitors: what role should they play?

Abstract

The development of finasteride (PROSCAR, Merck & Co., Whitehouse Station, NJ) for the treatment of benign prostatic hyperplasia (BPH) has had variable results. Numerous short-term and long-term studies comparing finasteride with placebo have been reported. The results suggest that, physiologically, treatment with finasteride significantly decreases levels of both serum and intraprostatic dihydrotestosterone about 70% to 80% from baseline. In addition, total gland size decreases significantly-about 15% to 25% from baseline-particularly in the area of the periurethral zone of the prostate after finasteride treatment. Baseline prostate size has been found to have a relation to efficacy of finasteride treatment. The larger the prostate at baseline, the greater the urinary flow rate increase and symptom score decrease compared with placebo. Health-related quality-of-life parameters improved in those taking finasteride. In studies evaluating combination therapy, no significant differences were noted between those treated with an alpha blocker, such as terazosin or doxazosin in combination with finasteride, and those receiving an alpha blocker alone. Long-term finasteride versus placebo studies, such as the PROSCAR Long-Term Efficacy and Safety Study (PLESS), suggest that long-term medical therapy with finasteride affects the natural history of the disease as manifested by the decrease in rates of acute urinary retention and surgery. In patients who are "therapeutic responders," the degree of symptomatic improvement in those treated with finasteride appears to be equal to that seen in patients receiving alpha blockers. Prostate cancer detection rates did not differ between those treated with finasteride and those receiving a placebo. The results of these studies suggest that physicians must evaluate what role finasteride plays in the spectrum of available options for the treatment of BPH and lower urinary tract symptoms. Baseline parameters, such as prostate volume, prostate-specific antigen values, and whether to administer finasteride in combination with alpha blockers, are among the factors that will determine the appropriateness of such therapy.

• Authors: S A Kaplan
• Journal: Urology (Urology) Vol. 58 Issue 6 Suppl 1 Pg. 65-70; discussion 70 (Dec 2001) ISSN: 1527-9995 [Electronic] United States
• PMID: 11750255 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• 5-alpha Reductase Inhibitors
• Adrenergic alpha-Antagonists
• Enzyme Inhibitors
• Finasteride
• Terazosin
• Prostate-Specific Antigen
• Prazosin

Topics

• 5-alpha Reductase Inhibitors
• Adrenergic alpha-Antagonists (therapeutic use)
• Aged
• Aged, 80 and over
• Drug Therapy, Combination
• Enzyme Inhibitors (therapeutic use)
• Finasteride (therapeutic use)
• Humans
• Male
• Middle Aged
• Multicenter Studies as Topic
• Prazosin (analogs & derivatives, therapeutic use)
• Prostate (pathology)
• Prostate-Specific Antigen (blood)
• Prostatic Hyperplasia (blood, drug therapy, pathology)
• Quality of Life
• Randomized Controlled Trials as Topic